A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under the age of 60.

Introduction: In Europe, gastric adenocarcinoma (GADC) is commonly regarded as a disease of the elderly. This study aims to assess the proportion, characteristics, and survival of patients diagnosed with GADC under the age of 60.

Materials And Methods: This is a retrospective, multicentric, and analytical study conducted at four tertiary Spanish hospitals.

Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study.

Background: Missed oesophageal cancer (MEC) at upper gastrointestinal endoscopy (UGE) is poorly documented.

Objective: The objectives of this study were: (1) to assess the rate, predictors and survival of MEC; (2) to compare MEC and non-MEC tumours.

Methods: This was a retrospective cohort study conducted at four tertiary centres.

Characteristics and consequences of missed gastric cancer: A multicentric cohort study.

Background: Missed gastric cancer (MGC) is poorly documented in Mediterranean populations.

Aims: (1) To assess the rate, predictors and survival of MGC. (2) To compare MGC and non-MGC tumors.

Autologous haematopoietic stem cell transplantation in refractory Crohn's disease: Experience in our centre.

Introduction: Autologous haematopoietic stem cell transplantation (AHSCT) is an accepted treatment in refractory Crohn's disease (CD).

Material And Methods: Data on patients with refractory CD subjected to AHSCT are collected at the Hospital Universitario Ramón y Cajal in Madrid and the results obtained are described retrospectively.

Results: Seven patients in total have received AHSCT due to refractory CD in our centre.

Epistaxis in the cirrhotic patient: A complication to be considered.

Introduction: Epistaxis in cirrhotic patients is a common issue. However, the literature published to date is very scarce.

Material And Methods: Retrospective case series of patients with cirrhosis who presented with a significant epistaxis, between 2006 and 2016.

Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.

Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust.